<DOC>
	<DOCNO>NCT01286766</DOCNO>
	<brief_summary>Number patient plan The study adopt two parallel phase II study , P1 P0 arm , suggest Logan . The investigator hypothesize target ORR interest , P1=50 , low ORR , P0=25 treatment DCS DCF , respectively . Under assumption α-error=0.05 β-error= 0.2 , use sample size table A'Hern , 26 patient require per arm achieve desire statistical power . Finally , take 20 % drop-out rate consideration , overall number enrol patient 62 .</brief_summary>
	<brief_title>Neoadjuvant Combination Chemotherapy DCS ( Cisplatin + Docetaxel + S-1 ) DCF ( Docetaxel + Cisplatin + 5-FU ) Patients With Locally Advanced Gastric Adenocarcinoma</brief_title>
	<detailed_description>Treatment scheme - Screening period : D-21 D1 ( treatment day ) - Preoperative screening include EUS , laparoscopy ( optional ) , EGD abd-pelvic CT scan . - Preoperative clinical staging base guideline Japanese Gastric Cancer Association ( JGCA , 1998 ) - Tumor response assess every 2 cycle ( 6 week ) - Treatment repeat , . - 4 cycle - progressive disease - unacceptable toxicity - patient 's withdrawal - Gastric surgery perform within 4~6 week last dose chemotherapy - Gastric surgery curative aim include ≥ D2 LN dissection . - Patients receive R0 resection receive least 4-cycled adjuvant chemotherapy 5-FU cisplatin . - Palliative chemotherapy indicate inoperable progressive disease fail curative resection . 5-FU oxaliplatin combination recommend first-line therapy . - Follow survival repeat every 3 month 2 year Study period Patient enroll period 12 months. , follow-up duration 12 months. , result total study period 24 month</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically/cytologically confirm gastric adenocarcinoma Age 18 70 year old ECOG performance Status 0~1 Preoperative clinical stag Japanese Gastric Cancer Association ( JGCA ) : cT3N2 ( IIIB ) , cT4N03 ( IIIA~IV ) , M0 , P0 , H0 , CY0 No pretreatment ( radiotherapy chemotherapy ) gastric cancer Adequate organ function Hb ≥ 9.0 g/dL WBC ≥ 4,000/µL ANC ≥ 2,000/µL ( *ANC = Neutrophil segs ＋ Neutrophil band ) Platelet ≥ 100 × 103/ µL Total bilirubin : ≤ 1.5 × UNL CCr ≥ 60 ml/min ( laboratory CockcroftGault Formula ) AST/ALT , ALP : ≤ 2.5 × UNL Written inform consent Distant metastasis diagnosis cT12 Cancer gastroesophageal junction ( GEJ ) Poor oral intake absorption deficiency syndrome Gastric outlet obstruction , perforation bleed Medically uncontrollable chronic illness infection Pregnant lactate woman , woman childbearing potential employ adequate contraception History clinically significant cardiac disease Past concurrent history neoplasm last &lt; 5 year gastric cancer Prior gastrectomized patient Concomitant administration experimental drug investigation Peripheral neuropathy ≥ NCICTC grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>unresectable</keyword>
	<keyword>locally advanced</keyword>
</DOC>